Found 386 oncology trials
A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
TrialX API NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America).
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
TrialX API NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America).
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
NRG-GI007 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America).
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
NRG-GI007 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America).
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
UPCC 12122 SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibit
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib or abemaciclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation
Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma With Elevated LDH
This phase II trial investigates how well adding hydroxychloroquine to the standard treatment of dabrafenib and trametinib works to overcome resistance and delay disease progression in treating patients with stage IIIC or IV BRAF V600E/K melanoma. Giving hydroxychloroquine together with dabrafenib and trametinib may work better than dabrafenib and trametinib …
UPCC 22420: A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma
The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab) and to characterize the safety of each RP2D for selected treatment combinations. Patients from within the Penn Medicine Cancer Center will be approached as potential participants.
Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging HIV Infection and Inflammation
This study will look at the relationships between HIV infection, age and the immune system, and how these relate to the development of non-infectious illnesses such as heart disease, kidney disease, cancer, memory problems, and diabetes. Further, we will look at how demographic factors, behaviors, and social factors like social …
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
The first purpose of this study is to test the safety of the addition of a drug called inotuzumab to the usual chemotherapy drugs used for adolescent young adults (ages 18-39). Inotuzumab is investigational and is not FDA-approved. Additionally,this study is to compare any good and bad effects of using …
UPCC 07718: INSPIRE: A Multicenter Randomized Controlled Trial integrating health informatics in a scalable
We would like to rely on the Fred Hutchinson Cancer Research Center (FHCRC) as IRB of record for this study. We are doing this study to examine ways to improve the health of long-term survivors of bone marrow or blood stem cell transplant. We want to know if an online …
Please choose between Voice or SMS based delivery of verification code
or